Whitehawk Therapeutics (NASDAQ:WHWK) Coverage Initiated at Jones Trading

Investment analysts at Jones Trading began coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a research note issued to investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Jones Trading’s target price indicates a potential upside of 164.15% from the stock’s current price.

WHWK has been the topic of several other research reports. Wall Street Zen cut Whitehawk Therapeutics to a “strong sell” rating in a research note on Saturday, November 1st. Zacks Research upgraded shares of Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Whitehawk Therapeutics Price Performance

WHWK opened at $2.65 on Monday. The stock has a market capitalization of $124.89 million, a price-to-earnings ratio of 18.93 and a beta of 0.38. The firm has a fifty day simple moving average of $2.32. Whitehawk Therapeutics has a 12-month low of $1.39 and a 12-month high of $3.81.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.25. Whitehawk Therapeutics had a negative return on equity of 68.32% and a net margin of 99.42%.

Hedge Funds Weigh In On Whitehawk Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. acquired a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $2,552,000. Peapod Lane Capital LLC acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth $577,000. Dimensional Fund Advisors LP bought a new position in shares of Whitehawk Therapeutics during the 3rd quarter valued at $84,000. Avoro Capital Advisors LLC acquired a new stake in shares of Whitehawk Therapeutics in the 3rd quarter valued at $5,414,000. Finally, Suvretta Capital Management LLC bought a new stake in Whitehawk Therapeutics in the third quarter worth $7,030,000. Institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.